Baseline characteristics

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) · Source last updated 2021-08-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      205

   2. group Id

      BG001

      value

      97

   3. group Id

      BG002

      value

      302

   units

   Participants

groups

1. description

   Participants received everolimus 10 mg once daily BSC throughout the study

   id

   BG000

   title

   Everolimus + BSC

2. description

   Participants received matching placebo once daily plus BSC during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period

   id

   BG001

   title

   Placebo+BSC

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            11.70

            value

            62.9

         2. group Id

            BG001

            spread

            12.89

            value

            59.4

         3. group Id

            BG002

            spread

            12.18

            value

            61.7

   description

   Age continuous at Baseline: Blinded Period

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            116

         2. group Id

            BG001

            value

            44

         3. group Id

            BG002

            value

            160

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            89

         2. group Id

            BG001

            value

            53

         3. group Id

            BG002

            value

            142

         title

         Male

   description

   Gender at Baseline: Blinded period

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            162

         2. group Id

            BG001

            value

            68

         3. group Id

            BG002

            value

            230

         title

         Caucasian

      2. measurements

         1. group Id

            BG000

            value

            32

         2. group Id

            BG001

            value

            18

         3. group Id

            BG002

            value

            50

         title

         Asian

      3. measurements

         1. group Id

            BG000

            value

            6

         2. group Id

            BG001

            value

            9

         3. group Id

            BG002

            value

            15

         title

         Black

      4. measurements

         1. group Id

            BG000

            value

            5

         2. group Id

            BG001

            value

            2

         3. group Id

            BG002

            value

            7

         title

         Other

   description

   Race at Baseline: Blinded-period

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race/Ethnicity, Customized

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice